HCP
GSK icon

Hexagon Capital Partners’s GSK GSK Stock Holding History

Hexagon Capital Partners’s Portfolio GSK Stock Details GSK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$342K Buy
6,529
+368
+6% +$19.5K 0.05% 181
2026
Q1 		$340K Buy
+6,161
New +$334K 0.05% 178
2025
Q2 		– Sell
-7,839
Closed -$304K – 755
2025
Q1 		$304K Buy
7,839
+578
+8% +$21.2K 0.06% 155
2024
Q4 		$246K Sell
7,261
-2,308
-24% -$83.1K 0.04% 184
2024
Q3 		$391K Sell
9,569
-398
-4% -$16.3K 0.08% 120
2024
Q2 		$384K Buy
9,967
+791
+9% +$33.3K 0.08% 125
2024
Q1 		$393K Buy
9,176
+76
+0.8% +$3.13K 0.09% 119
2023
Q4 		$337K Buy
9,100
+4,067
+81% +$146K 0.08% 124
2023
Q3 		$182K Buy
5,033
+838
+20% +$29.7K 0.05% 181
2023
Q2 		$150K Buy
4,195
+1,329
+46% +$47.7K 0.04% 203
2023
Q1 		$102K Sell
2,866
-68
-2% -$2.38K 0.03% 238
2022
Q4 		$103K Buy
2,934
+253
+9% +$8.43K 0.03% 241
2022
Q3 		$79K Buy
2,681
+1,179
+78% +$44.7K 0.02% 281
2022
Q2 		$82K Buy
1,502
+1,010
+205% +$55.8K 0.02% 290
2022
Q1 		$27K Sell
492
-82
-14% -$4.45K 0.01% 456
2021
Q4 		$32K Sell
574
-112
-16% -$5.83K 0.01% 420
2021
Q3 		$33K Hold
686
– – 0.01% 398
2021
Q2 		$34K Sell
686
-1,224
-64% -$58.8K 0.01% 378
2021
Q1 		$85K Sell
1,910
-277
-13% -$12.6K 0.02% 250
2020
Q4 		$100K Sell
2,187
-58
-3% -$2.66K 0.03% 191
2020
Q3 		$96K Buy
+2,245
New +$112K 0.03% 181

Other funds holding GSK

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
JEST
JTC Employer Solutions Trustee St Helier, Jersey $1.25B AUM 41.83% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Hexagon Capital Partners's GSK Position: Q2 2026 in Review

Hexagon Capital Partners increased its GSK (GSK) stake by 6% in Q2 2026, buying an estimated $19.5K and bringing the position to 6,529 shares worth $342K. The position accounts for 0.05% of the portfolio, ranked #181.

Hexagon Capital Partners first reported a position in GSK in Q3 2020 and has held it in 21 quarters since. The position peaked at $393K in Q1 2024. 1,037 funds tracked by Wall St. Rank hold GSK as of Q2 2026.

  • Hexagon Capital Partners held 6,529 shares of GSK worth $342K as of Q2 2026.
  • Hexagon Capital Partners bought 368 GSK shares in Q2 2026, an estimated $19.5K.
  • GSK made up 0.05% of Hexagon Capital Partners's portfolio in Q2 2026, its #181 holding.
  • Hexagon Capital Partners first reported a position in GSK in Q3 2020 and has held it in 21 quarters since.
  • Hexagon Capital Partners's GSK position peaked at $393K in Q1 2024.
  • 1,037 funds tracked by Wall St. Rank held GSK as of Q2 2026.

Based on Hexagon Capital Partners's 13F filing for Q2 2026, filed 7 Aug 2026.